Lineage Cell Therapeutics Inc - Asset Resilience Ratio
Lineage Cell Therapeutics Inc (LCTX) has an Asset Resilience Ratio of 0.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Lineage Cell Therapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Lineage Cell Therapeutics Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Lineage Cell Therapeutics Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Lineage Cell Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Lineage Cell Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $23.00K | 0.03% |
| Total Liquid Assets | $23.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Lineage Cell Therapeutics Inc maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lineage Cell Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Lineage Cell Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Lineage Cell Therapeutics Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Lineage Cell Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.78% | $2.02 Million | $113.22 Million | +1.73pp |
| 2023-12-31 | 0.05% | $50.00K | $101.02 Million | -37.57pp |
| 2022-12-31 | 37.62% | $46.52 Million | $123.66 Million | +36.12pp |
| 2021-12-31 | 1.50% | $2.62 Million | $174.54 Million | -6.82pp |
| 2020-12-31 | 8.32% | $8.98 Million | $107.95 Million | -8.59pp |
| 2019-12-31 | 16.91% | $21.22 Million | $125.48 Million | +9.87pp |
| 2018-12-31 | 7.04% | $7.15 Million | $101.66 Million | +6.27pp |
| 2017-12-31 | 0.77% | $1.34 Million | $173.24 Million | +0.33pp |
| 2016-12-31 | 0.44% | $627.00K | $142.57 Million | -0.36pp |
| 2015-12-31 | 0.80% | $753.00K | $94.66 Million | +0.79pp |
| 2014-12-31 | 0.00% | $3.00K | $74.90 Million | -- |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more